Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase 4 1Phase 1/2 1Phase 1 1

Status

Completed 7Recruiting 4Unknown 2Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Pseudomyxoma Peritonei 1Peripheral Nervous System Diseases 1Ototoxicity 1Neoplasms, Cystic, Mucinous, and Serous 1Adenocarcinoma, Mucinous 1

Interventions

Cisplatin 270Oxaliplatin 195Carboplatin 191Capecitabine 184Docetaxel 178apatinib 164Paclitaxel 163Bevacizumab 159Gemcitabine 156Radiotherapy 147camrelizumab 146Fluorouracil 144Cyclophosphamide 126Irinotecan 120Drug Therapy 119sintilimab 108Etoposide 99anlotinib 90S 1 (combination) 89Leucovorin 86pembrolizumab 85toripalimab 78Pemetrexed 78Doxorubicin 77tislelizumab 76Dexamethasone 71Trastuzumab 65Neoadjuvant Therapy 65Rituximab 62Cetuximab 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Unknown × Acetylcysteine × Clear all
NCT06297369 2024-03-07

Evaluation of the Effect of N-acetylcysteine in Preventing Cisplatin-Induced Toxicities in Cancer Patients

Ain Shams University

Phase 2 Unknown
60 enrolled

Ototoxicity, Peripheral Nervous System Diseases

NCT03976973 2022-03-15

BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei

Mucpharm Pty Ltd

Phase 2 Unknown
62 enrolled

Adenocarcinoma, Mucinous, Pseudomyxoma Peritonei, Neoplasms, Cystic, Mucinous, and Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡